Archive:
Interview mit Dr.med. H.-J. Helming, Vorsitzender des Vorstandes KVBB und Lutz O. Freiberg, KVBB-Unternehmensbereichsleiter und Geschäftsführer der IGiB.
31.03.2016
The KV RegioMed program for structural migration in the Templin region is more than just a pilot project. It is not merely an attempt to use the given prevalence rates in a region – in the Uckermark region, specifically in the Templin area – to make predictions about diseases in the coming years and decades, but rather to draw conclusions about how healthcare restructuring should look in the foreseeable future in order to create a more targeted and thus better-suited regional healthcare system through inpatient and outpatient structural migration.
31.03.2016
Cataracts, also commonly known as cataracts, are one of the most common reasons for surgical intervention in Germany. Consequently, the surgical methods and materials used are also of great importance. Based on a retrospective routine data analysis, the WIG2 Institute examined the health economic consequences of different lens materials in the surgical treatment of cataracts. The comparison of hydrophobic and hydrophilic acrylate lenses shows which implants have a lower risk of complications.
31.03.2016
The affiliated doctor system is a long-established form of integrative and cross-sectoral care (Hahn et al., 2015a, 2015b; Wienke and Mündnich, 2011). Both care approaches are also currently in the focus of German politics: (More) integrated care has been repeatedly demanded for almost 20 years now (Mühlbacher et al., 2006). The innovation fund, which became German law in the Supply Strengthening Act of June 10, 2015, provides 225 million euros per year to "new forms of care that aim to improve cross-sector care and have sufficient potential to be permanently included in care". (German Bundestag, 2015). In the classic understanding of affiliated doctors, a doctor who primarily works as a panel doctor/outpatient treats his patients using inpatient resources in a hospital in an affiliated department. For this purpose, the attending doctor has a contract with the hospital to be able to use the infrastructure (including staff) in the hospital. The attending doctor and the hospital are paid independently of each other. While the affiliated doctor accounts for his work using the uniform assessment scale (EBM), the hospital receives a so-called affiliated doctor DRG.
31.03.2016
On January 1st, 2012, with the GKV-VStG, the legislator laid the foundation for the development of a new care structure, the "outpatient specialist medical care" (ASV). With the new version of § 116b SGB V (§ 116b SGB V "new"), since the beginning of 2012, not only hospitals but also contract doctors have been included in the regulations. The ASV essentially pursues two goals: Firstly, it is intended to contribute to overcoming the sectoral boundaries in the German health care system and, secondly, to achieve improved interdisciplinary coordination of diagnostics and therapy among the service providers. For the first time in the German healthcare system, the ASV is intended to open up the possibility for registered panel doctors and hospitals to work and work together across sectors under the same conditions (cf. e.g. G-BA 2015a; Klakow-Franck 2014b: 154 and 2015: 6). The introduction of the ASV was not least in the interest of panel doctors (cf. e.g. Klakow-Franck 2014b: 153), because under the existing regulations (§116b SGB V "old") they had to fear that the comparatively financially strong hospitals there is increasing competition with a correspondingly tougher competitive situation in the healthcare market. Contract doctors had also repeatedly filed lawsuits against hospital approvals under Section 116b SGB V "old" (cf. SVR 2012: 259).
31.03.2016
The affiliated doctor system is a long-established form of integrative and cross-sectoral care (Hahn et al., 2015a, 2015b; Wienke and Mündnich, 2011). Both care approaches are also currently in the focus of German politics: (More) integrated care has been repeatedly demanded for almost 20 years now (Mühlbacher et al., 2006). The innovation fund, which became German law in the Supply Strengthening Act of June 10, 2015, provides 225 million euros per year to "new forms of care that aim to improve cross-sector care and have sufficient potential to be permanently included in care". (German Bundestag, 2015). In the classic understanding of affiliated doctors, a doctor who primarily works as a panel doctor/outpatient treats his patients using inpatient resources in a hospital in an affiliated department. For this purpose, the attending doctor has a contract with the hospital to be able to use the infrastructure (including staff) in the hospital. The attending doctor and the hospital are paid independently of each other. While the affiliated doctor accounts for his work using the uniform assessment scale (EBM), the hospital receives a so-called affiliated doctor DRG.
31.03.2016
When evaluating new drugs for the treatment of cancer, the endpoint survival is the main focus. Many of these new drugs can be shown to have a survival advantage compared to the previously available treatment options. However, it is often emphasized that this is usually only “two to three months” (e.g. Lauterbach 2015, Fojo et al. 2014). This additional survival time is often perceived as insufficient and complaints are also made that the time gained in this way often does not provide an adequate quality of life. Furthermore, the new active ingredients have not been sufficiently tested. The use of the usually high-priced drugs is therefore often not worth the money. Due to the high health policy importance of the assumption that new therapies only offer "two to three months" additional survival time, this study should examine whether this common assumption is in line with the facts. The basis for this is the resolutions for the evaluation of new drugs according to the Drug Market Reorganization Act (AMNOG), which all new active ingredients have had to undergo since 2011 in order to demonstrate their additional benefit compared to the so-called appropriate comparative therapy.
31.03.2016
Zeitgleich zum Erscheinen dieses Artikels bewertet der Expertenrat des Innovationsfonds derzeit die Anträge der ersten Förderrunde. Der folgende Beitrag spiegelt die Erfahrungen der letzten Wochen und Monate wider, die aus der Mitarbeit bei mehreren Anträgen resultieren. Welche Projekte und Anträge tatsächlich Erfolg haben, werden jedoch erst die Förderentscheidungen zeigen. Eines lässt sich aber bereits festhalten: Die lange währende Unsicherheit über die Rahmenbedingungen war für viele Antragsteller schwierig. Lange Zeit mussten alle Beteiligten davon ausgehen, dass die Finanzmittel nicht zwischen den Jahren übertragbar seien, so dass die wichtigsten Förderentscheidungen schon in diesem Jahr fallen und die Mittel der Folgejahre binden würden. Es entstand das Gefühl, 2016 unbedingt teilnehmen zu müssen. Dies führte zu Hunderten von Anträgen in beiden Fördertöpfen. Momentan sieht es so aus (Stand Juli 2016), als seien die Mittel doch übertragbar, so dass die Fördersumme eines Jahres auf drei bis vier Jahre aufgeteilt wird. Damit kann nur ein kleiner Anteil der eingereichten Projekte tatsächlich gefördert werden. Das mag man im Sinne des Wettbewerbs begrüßen. Andererseits hat sich so die ganze Aufmerksamkeit vieler Akteure auf den Fonds gerichtet, was Innovationen in anderen Bereichen, etwa den nach wie vor möglichen „normalen“ Selektivverträgen möglicherweise beeinträchtigt hat. Es wäre sinnvoll, durch implizite Steuerung im nächsten Jahr Anreize derart zu setzen, dass die Akteure sich auf eine geringere Zahl von Anträgen konzentrieren. Auch die Tatsache, dass die Evaluation noch während des Förderzeitraums abgeschlossen werden muss, ist zu hinterfragen, weil dies den möglichen Beobachtungszeitraum in den Projekten weiter verkürzt. Um klarere Aussagen über die Effekte der Vorhaben zu erhalten, sollte dies geändert werde.
31.03.2016
Stellungnahme zum Vorbericht „Planungsrelevante Qualitätsindikatoren des Institutes für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG) in der Fassung vom 18.7.2016 gemäß Auftrag des Gemeinsamen Bundesausschusses vom 17.3.2016
31.03.2016
Interview with Dr. Dominik Graf von Stillfried, Managing Director of Zi Berlin.